Emerging Biomarker Tests May Aid Early Autism Identification

The Potential for Earlier Recognition of Autism Traits

Recent studies explore how biomarker tests incorporating artificial intelligence (AI) and microbial analysis might help identify autism-related traits earlier than current behavioral observation methods. A 2024 study in Nature Communications found certain microbially-derived metabolites in urine samples that correlated with autism traits in some children, while separate AI-assisted analysis of stool samples demonstrated preliminary accuracy in small pilot studies.

Earlier recognition of autism traits—often possible by age 2.5—allows for timely access to support services and accommodations. Current diagnostic approaches primarily rely on behavioral observations, which can delay identification. Biomarker tests might eventually provide complementary screening tools to help reduce these delays.

Earlier recognition of autism traits—often possible by age 2.5—allows for timely access to support services and accommodations.

Developing Technologies

Several approaches are under investigation:

• Urinary metabolites: The 2024 Nature Communications study identified elevated levels of specific microbially-derived compounds in urine samples from some autistic children, suggesting potential as a screening tool for certain autism subtypes.
• AI-assisted stool analysis: Research from the Chinese University of Hong Kong uses AI to analyze gut microbiome patterns in stool samples, with early results showing 82% sensitivity and 88% specificity in small trials.
• Eye-tracking measures: As noted in Contemporary Pediatrics, some clinics are exploring visual attention patterns as potential screening aids.

Current Limitations

While promising, these methods remain investigational:

• The urine metabolite findings apply only to certain autism subtypes
• The CUHK stool test's reported 82-88% accuracy means it would still miss some cases and flag others incorrectly
• Commercial tests like ClearStrand-ASD (analyzing hair samples) and MSX Metagenie® (stool analysis) have not published peer-reviewed validation data, despite being available in some markets

Dr. Emily Jones, a developmental neuroscientist at Birkbeck, University of London (unaffiliated with these studies), cautions: "These technological advances are exciting, but we need rigorous, independent replication across diverse populations before considering clinical implementation."

Regulatory and Practical Considerations

The FDA has granted Breakthrough Device designation to some tests like ClearStrand-ASD—a status that accelerates regulatory review but does not constitute approval or confirm effectiveness. Parents should understand that:

1. These are screening tools, not diagnostic tests 2. Positive results require follow-up with comprehensive diagnostic evaluation 3. No biomarker test currently replaces gold-standard clinical assessment

Ongoing research aims to validate these methods through larger studies and standardize testing protocols. If validated, they may eventually help reduce delays in accessing support services.